STAFF

> University Academic Staffback
A photo of Dr SETO Wai Kay, Walter
Dr SETO Wai Kay, Walter
Clinical Associate Professor
MBBS(HK) MD(HK) MRCP (UK)
FRCP (Edin, Glasg, Lond) FHKCP FHKAM (Medicine)
an email logo wkseto@hku.hk
a telephone logo 2255-3994
a fax logo 2255-5411

Biography

Dr. Seto Wai Kay Walter graduated from the University of Hong Kong in 2003 and received his Fellowship in Gastroenterology and Hepatology in 2010 from the Hong Kong College of Physicians. In 2012, he received his Doctor of Medicine from the University of Hong Kong, and was a visiting post-doctoral fellow in Baylor College of Medicine, Houston, Texas. He is currently a Clinical Associate Professor in the Department of Medicine, the University of Hong Kong, Hong Kong, and Consultant of Medicine and Assistant Hospital Chief Executive (Research) in the University of Hong Kong-Shenzhen Hospital, Shenzhen, China. He has published more than 100 articles in high-impact peer-reviewed journals, including several in high-impact peer-reviewed journals including Journal of Clinical Oncology, Gut, Hepatology, Journal of Hepatology and the American Journal of Gastroenterology as first author, and is a frequent reviewer of more than 15 peer-reviewed journals in Medicine and Gastroenterology. He has been awarded the Distinguished Research Paper Award for Young Investigator (2012, 2013, 2014 and 2015) from the Hong Kong College of Physicians, and the Distinguished Young Fellow from the Hong Kong Academy of Medicine (2013).

Research Profile

  • Gastroenterology and Hepatology
  • Clinical and translational research in viral hepatitis and liver fibrosis

Selected Publications

  1. Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu K, Gill H, Lam YF, Lie AK, Lai CL, Kwong YL, Yuen MF. Hepatitis B reactivation in patients with prior HBV exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 2014; 32: 3736-43. (2015 impact factor 20.982)
  2. Seto WK, Hui AJ, Wong VW, Wong GL, Liu K, Lai CL, Yuen MF, Chan HL. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicenter prospective study. Gut 2015; 64: 667-72. (2015 impact factor 14.921)
  3. Seto WK, Yuen MF.  “Immune tolerance” in HBV infection: danger lurks. Nat Rev Gastroenterol Hepatol 2016 13:627-628. (2015 impact factor 14.435)
  4. Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu K, Gill H, Lam YF, Lau HY, Cheung KS, Lie AK, Lai CL, Kwong YL, Yuen MF. Hepatitis B reactgivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study. Hepatology 2017 in press (2015 impact factor 11.711).
  5. Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and HBsAg seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013; 58: 923-31. (2015 impact factor 11.711)
  6. Seto WK, Wong DK, Fung J, Hung IF, Fong DY, Yuen JC, Tong T, Lai CL, Yuen MF. A large case-control study on the predictability of hepatitis B surface antigen three years before HBsAg seroclearance. Hepatology 2012 56: 812-9. (2015 impact factor 11.711)
  7. Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, Lai CL, Yuen MF. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2013; 4:709-16. (2015 impact factor 10.390)
  8. Seto WK, Lai CL, Fung J, Wong DK, Yuen JC, Hung IF, Yuen MF. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol 2011; 55(3): 522-8. (2015 impact factor 10.390)
  9. Seto WK, Lai CL, Fung J, Hung IF, Yuen J, Young J, Wong DK, Yuen MF. Natural history of chronic hepatitis C: genotype 1 versus genotype 6. J Hepatol 2010; 53: 444-8. (2015 impact factor 10.390)
  10. Seto WK, Wong DK, Chan TS, Hwang YY, Wong DK, Fung J, Liu K, Gill H, Lam YF, Cheung KS, Lie AK, Lai CL, Kwong YL, Yuen MF.  Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy. Am J Gastroenterol 2016; 111:1788-1795. (2015 impact factor 10.383)

Key Offices

  1. Assistant Hospital Chief Executive (Research), HKU-Shenzhen Hospital
  2. Consultant, Medicine, HKU-Shenzhen Hospital
  3. Honorary Lecturer, School of Professional and Continuing Education (SPACE), The University of Hong Kong
  4. Scientific Research Committee, Hong Kong Liver Foundation
  5. Fellow, Hong Kong Society of Gastroenterology